Avalyn Pharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Avalyn Pharma Inc. details progress in its Phase 2b clinical trial for AP01 and Phase 2 trial for AP02, alongside a robust cash position post-IPO, while acknowledging ongoing development risks.